You are here

  • Home
  • Archive
  • Volume 23, Issue Suppl 1
  • CP-035 Economic impact of aflibercept optimisation for the treatment of age related macular degeneration refractory to bevacizumab and/or ranibizumab

Article metrics

Article menu
Download PDFPDF
Clinical pharmacy
CP-035 Economic impact of aflibercept optimisation for the treatment of age related macular degeneration refractory to bevacizumab and/or ranibizumab

 

Online download statistics by month:

Online download statistics by month: February 2016 to March 2024

AbstractFullPdf
Feb 2016400
Apr 2016103
Jun 2016400
Jul 2016603
Aug 2016100
Sep 2016300
Oct 2016500
Nov 2016400
Dec 2016300
Jan 2017200
Feb 20172600
Mar 20171400
Apr 2017400
May 2017803
Jun 20171600
Jul 2017600
Aug 2017400
Sep 20172803
Oct 2017800
Nov 20172201
Dec 20171801
Jan 2018600
Feb 20181802
Mar 20182400
Apr 20181201
May 20187000
Jun 20181000
Jul 20181400
Aug 20181400
Sep 20181400
Oct 20183000
Nov 2018800
Dec 20182400
Jan 20191200
Feb 20191400
Mar 2019400
Apr 2019401
May 2019200
Jul 2019601
Aug 2019202
Sep 20191400
Oct 20191100
Nov 2019600
Dec 20191001
Jan 2020400
Feb 20201200
Mar 2020800
Apr 2020200
May 2020400
Jun 20201200
Jul 20201201
Aug 2020600
Sep 20201402
Oct 20207000
Nov 20207402
Dec 20201000
Jan 2021200
Feb 20211000
Mar 2021200
Apr 20212602
May 2021200
Aug 2021001
Oct 2021400
Nov 20211402
Dec 20211601
Jan 2022400
Feb 2022400
Mar 2022800
May 2022600
Jun 2022600
Jul 2022400
Aug 20221001
Sep 2022600
Oct 20222000
Nov 20221800
Dec 20221400
Jan 2023400
Feb 2023400
Mar 2023600
Apr 2023200
May 2023400
Jun 2023900
Jul 2023600
Aug 2023400
Sep 20231600
Nov 2023400
Dec 20231000
Jan 2024400
Feb 20245400
Mar 20241200
Total1059034